New York, New York – (Newsfile Corp. – January 25, 2025) – WHY: Rosen Law Firm, a global law firm for investor rights, reminds buyers of securities from Cassava Sciences, Inc. (NASDAQ: NASDAQ š Between February 7, 2024 and November 24, 2024, both data including (the “class period”),) To the important one February 10, 2025 deadline for the main plaintiff.
Well and: If you bought Cassava value papers during the collection period, you may be entitled to compensation without paying expenses or costs in the context of a success fee agreement.
What to do next: To take part in the Cassava collection, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, ESQ. to. Call us free of charge at 866-767-3653 or send us an email to Case@rosenegal.com to receive information on the class action. A class action has already been submitted. If you want to appear as the main plaintiff, you have to call the court At the latest on February 10, 2025. A main plaintiff is a representative party that acts on behalf of other group members when managing the legal dispute.
Why roses law: We encourage investors to choose qualified consultants who have a track record in management positions. Companies that issue messages often do not have comparable experiences, resources or noteworthy recognition from colleagues. Many of these companies do not lead actual investigators, but are only means by means of a man who convey clients or work with law firms that actually process the cases. Be smart when choosing your consultant. The Rosen law firm represents investors all over the world and concentrates in their practice on securities collection lawsuits and shareholder derivative lawsuits. At that time, the Rosen law firm reached the largest agreement in a collection of securities against a Chinese company. The Rosen law firm was elected in 1st place by the ISS Securities Class action (Wa š Services for the number of comparisons in securities collection lawsuits in 2017. The company has been one of the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company secured over $ 438 million for investors. In 2020, founding partner Laurence Rosen from Law360 was appointed Titan of PlaintenTiffs’ bar. Many of the law firm’s lawyers were recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, the accused gave the wrong impression during the entire collection period, they had reliable information about the drug prospects and the expected growth of Cassava and at the same time minimized the risk of a possible failure of the medicine. In truth, however, Cassava’s repeated expressions of trust in Simufilam, the leading medication candidate of Cassava, and his confidence in the evaluation of the statistically insignificant data from the phase 2 study behind the reality of Simufilam’s potential; Cassava simply did not have a medication that could slow down the progression of Alzheimer’s disease, even if an attempt was made to treat only slight and moderate cases. When the real details came to light, the complaint states that investors had caused damage.
To take part in the Cassava collection, go to https://rosenlegal.com/submit-form/?case_id=22374 and call Phillip Kim, ESQ. to. Call us free of charge at 866-767-3653 or send us an email to Case@rosenegal.com to receive information on the class action.
No class was certified. Until the certification of a course, you will not be represented by legal advisors unless you commission you. You can choose a lawyer of your choice. At this point you can also remain an absent course participant and do not do anything. The ability of an investor to participate in a possible future recovery does not depend on whether he appears as the main plaintiff.
Follow us for updates to LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (nasdaq :): https: //www.facebook.com/rosenlawfirm.
Lawyer advertising. Earlier results do not guarantee a similar result.
—————-
To display the source version of this press release, please visit https://www.newsfilecorp.com/release/238405
